Essentiality and toxicity of vanadium supplements in health and pathology

Journal of Physiology and Pharmacology

Volumn 65, Issue 5, 2014, Pages 603-611

  Gruzewska, K ^a   Michno, Anna ^a   Pawelczyk, T ^a   Bielarczyk, H ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Cancer; Diabetes; Heart disease; Hypertension; Lipid profile; Neuroprotection; Neurotoxicity; Vanadium

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE 6 PHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; STRESS ACTIVATED PROTEIN KINASE; TRIACYLGLYCEROL; VANADIUM DERIVATIVE; ANTINEOPLASTIC AGENT; CARCINOGEN; CARDIOTONIC AGENT; NEUROPROTECTIVE AGENT; VANADIUM;

BIOLOGICAL ACTIVITY; CARCINOGENESIS; CARCINOGENIC ACTIVITY; DIABETES MELLITUS; DRUG METABOLISM; ENZYME INHIBITION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HEART DISEASE; HUMAN; HYPERTENSION; LIPID METABOLISM; LIPOGENESIS; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PATHOLOGY; REGULATORY MECHANISM; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; DIET SUPPLEMENTATION; DRUG EFFECTS; HEART DISEASES; NEOPLASMS; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; CARCINOGENS; CARDIOTONIC AGENTS; DIABETES MELLITUS; DIETARY SUPPLEMENTS; HEART DISEASES; HUMANS; HYPERTENSION; LIPID METABOLISM; NEOPLASMS; NEUROPROTECTIVE AGENTS; VANADIUM;

EID: 84908395352     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Korbecki J, Baranowska-Bosiacka I, Gutowska I, Chlubek D. Biochemical and medical importance of vanadium compounds. Acta Biochim Pol 2012; 59: 195-200.
2. Shechter Y, Goldwaser I, Mironchik M, Fridkin M, Gefel D. Historic perspective and recent developments on the insulinlike actions of vanadium; toward developing vanadiumbased drugs for diabetes. Coord Chem Rev 2003; 237: 3-11.
3. Urban J, Antonowicz-Juchniewicz J, Andrzejak R. Wanad - zagrozenia i nadzieje. Medycyna Praktyczna 2001; 52: 125-133.
4. Mukherjee B, Patra B, Mahapatra S, Banerjee P, Tiwari A, Chatterjee M. Vanadium - an element of atypical biological significance. Toxicol Lett 2004; 150; 135-143.
5. [No authors listed]. Vanadium/Vanadyl sulphate. Alternative Med Rev 2009; 14: 177-180.
6. Ozturk N, Olgar Y, Ozdemir S. Trace elements in diabetic cardiomyopathy: an electrophysiological overview. World J Diabetes 2013; 4: 92-100.
7. Arya GS, Hedaytullah MD, Yadav RA, Sachan K. Treating diabetes mellitus with vanadium salts - a future prospectus: Int J Pharm Sci Rev Res 2011; 8: 183-185.
8. Afkhami-Ardekani M, Karimi M, Mohammadi SM, Nourani F, Soheilikhah S. Comparison of the effects of sodium metavanadate and zinc sulfate supplementation an lipid and glucose in patients with type 2 diabetes. Iran J Diabetes Obes 2009; 1: 22-29.
9. Mehdi MZ, Srivastava AK. Organo-vanadium compounds are potent activators of the protein kinase B signalling pathway and protein tyrosine phosphorylation: mechanism of insulinomimesis. Arch Biochem Biophys 2005; 440: 158-164.
10. Goldwasar I, Gefel D. Gershonov E, Fridkin M, Shechter Y. Insulin-like effects of vanadium: basic and clinical implications. J Inorg Biochem 2000; 80: 21-25.
11. Suenaga A, Ueki H. Effect of orthovanadate on platelet aggregation induced by platelet-activating factor. Biol Pharm Bull 2004; 27: 1859-1863.
12. Wei D, Li M, Ding W. Effect of vanadate on gene expression of the insulin signalling pathway in skeletal muscle of streptozotocin-induced diabetic rats. J Biol Inorg Chem 2007; 12: 1265-1273.
13. Park SJ, Youn C, Hyun JW, You HJ. The anti-obesity effect of natural vanadium-containing Jeju ground water. Biol Trace Elem Res 2013; 151: 294-300.
14. Huang M, Wu Y, Wang N, Wang Z, Zhao P, Yang X. Is the hypoglycemic action of vanadium compounds related to the suppression of feeding? Biol Trace Elem Res 2014; 157: 242-248.
15. Aureliano M, Gandara RM. Decavanadate effects in biological systems. J Inorg Biochem 2005; 99: 979-985.
16. Thompson KH, Orvig C. Vanadium in diabetes - 100 years from Phase 0 to Phase I. J Inorg Biochem 2006; 100: 1925-1935.
17. Takada Y, Hashimoto M, Kasahara J. Cytoprotective effect of sodium orthovanadate on ischemia/reperfusion-induced injury in the rat heart involves Akt activation and inhibition of fodrin breakdown and apoptosis. J Pharmacol Exp Ther 2004; 311: 1249-1255.
18. Marzban L, McNeill JH. Insulin-like actions of vanadium: potential as a therapeutic agent. J Trace Elem Exp Med 2003; 16: 253-267.
19. Willsky GR, Chi LH, Liang Y, Gaile DP, Hu Z, Crans DC. Diabetes-altered gene expression in rat skeletal muscle corrected by oral administration of vanadyl sulphate. Physiol Genomics 2006; 26: 192-201.
20. Barceloux DG. Vanadium. Clin Toxicol 1999; 37: 265-278.
21. Bose S, Farah MA, Jung H, Lee JH, Kim Y. Molecular mechanism of bis(maltolato)oxovanadium (IV)-induced insulin signalling in 3T3-L1 and IM9 cells: impact of dexamethasone. J Mol Endocrinol 2007; 38: 627-649.
22. Hiromura M, Sakurai H. Action mechanism of metalloallixin complexes as antidiabetic agents. Pure Appl Chem 2008; 12: 2727-2733.
23. Kawabe K, Yoshikawa Y, Adachi Y, Sakurai H. Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes. Life Sci 2006; 78: 2860-2866.
24. Li SH, McNeill JH. In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats. Mol Cell Biochem 2001; 217: 121-129.
25. Seale AP, de Jesus LA, Park M, Kim YS. Vanadium and insulin increase adiponectin production in 3T3-L1 adipocytes. Pharmacol Res 2006; 54: 30-38.
26. Garcia-Vicente S, Yraola F, Marti L, et al. Oral insulinmimetic compounds that act independently of insulin. Diabetes 2007; 56: 486-493.
27. Ivancsits S, Pilger A, Diem E, Schaffer A, Rudiger HW. Vanadate induces DNA strand breaks in cultured human fibroblasts at doses relevant to occupational exposure. Mutat Res 2002; 519: 25-35.
28. Srivastava AK, Mehdi MZ. Insulino-mimetic and antidiabetic effects of vanadium compounds. Diabets Med 2005; 22: 2-13.
29. Zhao Y, Ye L, Liu H, et al. Vanadium compounds induced mitochondria permeability transition pore (PTP) opening related to oxidative stress. J Inorg Biochem 2010; 104: 371-378.
30. Thompson K.H, Lichter J, LeBel C, Scaife MC, McNeill JH, Orvig C. Vanadium treatment of type 2 diabetes - a view to the future. J Inorg Biochem 2009; 103: 554-558.
31. Shafrir E, Spielman S, Nachliel I, Khamaisi M, Bar-On H, Ziv E. Vanadium salts versus diabetes: an overview. Diabetes Metab Res Rev 2001; 17: 55-66.
32. Gonzalez-Villalva A, Pinon-Zarate G, De la Pena Diaz A, et al. The effect of vanadium on platelet function. Environ Toxicol Pharmacol 2011; 32: 447-456.
33. Facchini DM, Yuen VG, Battell ML, McNeill JH, Grynpas MD. The effects of vanadium treatment on bone in diabetic and non-diabetic rats. Bone 2006; 38: 368-377.
34. Bhuiyan MS, Fukunaga K. Cardioprotection by vanadium compounds targeting Akt-mediated signalling. J Pharmacol Sci 2009; 110: 1-13.
35. Gonzalez-Sanchez C, Bermudez-Pena C, Guerrero-Romero F, Trenzado CE, Montes-Bayon M, Sanz-Medel A, Llopis J. Effect of bis(maltolato)oxovanadium (IV) (BMOV) on selenium nutritional status in diabetic streptozotocin rats. Brit J Nutr 2012; 108: 893-899.
36. Sanchez-Gonzalez C, Lopez-Chaves C, Trenzado CE, et al. Changes in iron metabolism and oxidative status in STZ induced-diabetic rats treated with bis(maltolato)oxovanadium (IV) as an antidiabetic agent. ScientificWorldJournal 2014; 2014: 706074.
37. Dabros W, Adamczyk A, Ciurkot K, KordowiakAM. Vanadium compounds affect growth and morphology of human rhabdomyosarcoma cell line. Pol J Pathol 2011; 4: 262-268.
38. Bhuiyan S, Shioda N, Shibuya M. Iwabuchi Y, Fukunaga K. Activation of endothelial nitric oxide synthase by a vanadium compound ameliorates pressure overload-induced cardiac injury in ovariectomized rats. Hypertension 2009; 53: 57-63.
39. Bhuiyan S, Shibuya M, Shioda N. Cytoprotective effect of bis(1-oxy-2-pyridinethiolato)oxovanadiun (IV) on myocardial ischemia/reperfusion injury elicits inhibition of Fas ligand and Bim expression and elevation of FLIP expression. Eur J Pharmacol 2007; 571: 180-188.
40. Liem DA, Gho CC, Gho BC, et al. The tyrosine phosphatase inhibitor bis(maltolato)-oxovanadium attenuates myocardial reperfusion injury by opening ATP-sensitive potassium channels. J Pharmacol Exp Ther 2004; 309: 1256-1262.
41. Desoize B. Metals and metal compounds in cancer treatment. Anticancer Res 2004; 24: 1529-1544.
42. Rodriguez-Mercado JJ, Roldan-Reyes E, Altamirano- Lozano M. Genotoxic effects of vanadium (IV) in human peripheral blood cells. Toxicol Lett 2003; 144: 359-369.
43. Suwalsky M, Fierro P, Villena F, et al. Human ertythocytes and neuroblastoma cells are in vitro affected by sodium orthovanadate. Biochim Biophys Acta 2012; 1818: 2260-2270.
44. O’Connell B. Select vitamins and minerals in the management of diabetes. Diabetes Spectrum 2001; 14: 133-148.
45. Boden G, Chen X, Ruiz J, van Rossum GD, Turco S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 1996; 45: 1130-1135.
46. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulindependent diabetes mellitus. J Clin Invest 1995; 95: 2501-2509.
47. Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 1996; 45: 659-666.
48. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003; 26: 1277-1294.
49. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J Clin Endocr Metab 1995; 80: 3311-3320.
50. Ingram JL, Antao-Menezes A, Turpin EA, et al. Genomic analysis of human lung fibroblasts exposed to vanadium pentoxide to identify candidate genes for occupational bronchitis. Respir Res 2007; 8: 1-13.
51. Fraqueza G, Ohlin CA, Casey WH, Aureliano M. Sarcoplasmic reticulum calcium ATPase interactions with decaniobate, decavanadate, vanadate, tungstate and molybdate. J Inorg Biochem 2012; 107: 82-89.
52. Hasegawa Y, Hamada J, Morioka M, et al. Neuroprotective effect of postischemic administration of sodium orthovanadate in rats with transient middle cerebral artery occlusion. J Cerebr Blood Flow Metab 2003; 23: 1040-1051.
53. Wu Y, Huang M, Zhao P, Yang X. Vanadyl acetylacetonate upregulates PPARg and adiponectin expression in differentiated rat adipocytes. J Biol Inorg Chem 2013; 18: 623-631.
54. Zhao P, Yang X. Vanadium compounds modulate PPARg activity primarily by increasing PPARg protein levels in mouse insulinoma NIT-1 cells. Metallomics 2013; 5: 836-43.
55. Suwalsky M, Fierro P, Villena F, et al. Effects of sodium metavanadate on in vitro neuroblastoma and red blood cells. Arch Biochem Biophys 2013; 535: 248-256.
56. Shehzad S. The potential effect of vanadium compounds on glucose-6-phosphatase. Bioscience Horizons 2013; 6: 1-11.
57. Evangelou MA. Vanadium in cancer treatment. Crit Rev Oncol Hematol 2002; 42: 249-265.
58. Holko P, Ligeza J, Kisielewska J, Kordowiak AM, Klein A. The effect of vanadyl sulphate (VOSO4) on autocrine growth of human epithelial cancer cell lines. Pol J Pathol 2008; 59: 3-8.
59. Clancy HA, Sun H, Passantino L, et al. Gene expression changes in human lung cells exposed to arsenic, chromium, nickel or vanadium indicate the first steps in cancer. Metallomics 2012; 4: 784-793.
60. Shioda N, Ishigami T, Han F, et al. Activation of phosphatidyloinositol 3-kinase/protein kinase B pathway by a vanadyl compound mediates its neuroprotective effect in mouse brain ischemia. Neuroscience 2007; 148: 221-229.
61. Afeseh Ngwa H, Kanthasamy A, Anantharam V, et al. Vanadium induces dopaminergic neurotoxicity via protein kinase C delta dependent oxidative signaling mechanisms: relevance to etiopathogenesis of Parkinson’s disease. Toxicol Appl Pharmacol 2009; 240: 273-285.
62. D’Cruz OJ, Dong Y, Uckun FM. Potent dual anti-HIV and spermicidal activities of novel oxovanadium(V) complexes with thiourea non-nucleoside inhibitors of HIV-1 reverse transcriptase. Biochem Biophys Res Commun 2003; 302: 253-264.
63. Mohammad A. Various synthetic organic compounds with spermicidal activity. J Int Med Res 2014; 2: 1-14.
64. www.nih.gov
65. Villani P, Cordelli E, Leopardi P, et al. Evaluation of genotoxicity of oral exposure to tetravalent vanadium in vivo. Toxicol Lett 2007; 170: 11-18.
66. Tang H, Sun Y, Xiu Q, Lu H, Han H. Cyclooxygenase-2 induction requires activation of nuclear factor of activated Tcells in Beas-2B cells after vanadium exposure and plays an anti-apoptotic role. Arch Biochem Biophys 2007; 468: 92-99.
67. Soares SS, Gutierrez-Merino C, Aureliano M. Decavanadate induces mitochondrial membrane depolarization and inhibits oxygen consumption. J Inorg Biochem 2007; 101: 789-796.
68. Boulassel B, Sadeg N, Roussel O, Perrin M, Belhadj-Tahar H. Fatal poisoning by vanadium. Forensic Sci Int 2011; 206: 79-81.
69. Smith DM, Pickering RM, Lewith GT. A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus. Int J Med 2008; 101: 351-358.
70. Hogan GR. Comparative erythropoietic effects of three vanadium compounds. Sci Total Environ 2000; 256: 185-189.
71. Thompson KH, McNeil JH. Effect of vanadyl sulfate feeding on susceptibility to peroxidative change in diabetic rats. Res Commun Chem Pathol Pharmacol 1993; 80: 187-200.
72. Montiel-Davalos A, Gonzalez-Villava A, Rodriguez-Lara V, Montano LF, Fortoul TI, Lopez-Marure R. Vanadium pentoxide induces activation and death of endothelial cells. J Appl Toxicol 2012; 32: 26-33.
73. Capella MA, Capella LS, Valente RC. Vanadate-induced cell death is dissociated from H2O2 generation. Cell Biol Toxicol 2007; 23: 413-420.
74. Cusi K, Cukier S, Defronzo RA, Torres M, Puchulu FM, Redondo JC. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J Clin Endocriol Metab 2001; 86: 1410-1417.
75. Leon IE, Butenko N, Di Virgilio AL, et al. Vanadium and cancer treatment: antitumoral mechanisms of three oxidovanadium (IV) complexes on a human osteosarcoma cell line. J Inorg Biochem 2013; 127: 1-12.
76. Wender-Ozegowska E, Zawiejska A, Michalkowska-Wender G, Iciek R, Wender M, Brazert J. Metabolic syndrom in type 1 diabetes mellitus. Does it have any impact on the course of pregnancy? J Physiol Pharmacol 2011; 62: 567-573.
77. Toton E, Ignatowicz E, Bernard MK, Kujawski J, Rybczynska M. Evaluation of apoptotic activity of new condensed pyrazole derivatives. J Physiol Pharmacol 2013; 64: 115-123.
78. Reiter RJ, Tan DX, Korkmaz A, Fuentes-Broto L. Drugmediated ototoxicity and tinnitus: alleviation with melatonin. J Physiol Pharmacol 2011; 62: 151-157.